Key result
Anti-obesity medications are linked to meaningful weight reduction in ~63% of young adult cancer survivors.
Why the study?
Anti-obesity medications had not been studied in survivors of adolescent and young adult cancer.
Do anti-obesity medications reduce weight in survivors of adolescent and young adult cancer?
Cohort
Do anti-obesity medications reduce weight in survivors of adolescent and young adult cancer?
Anti-obesity medications are effective for achieving clinically meaningful weight reduction in survivors of adolescent and young adult cancer.
May aid weight management in AYA cancer survivors; leaves open need for randomized confirmation before practice change.
Anti-obesity medications (AOMs) have not been studied in survivors of adolescent and young adult (AYA) cancer. In this retrospective analysis, generalized additive mixed model with penalized spline described body mass index (BMI) over time among survivors of AYA cancer prescribed an AOM. Body weight and BMI at pre-AOM maximum and last follow-up were summarized, with 95% confidence intervals. Over a median follow-up time of 249 days, 63.4% of survivors had ≥5% weight reduction. The proportion of survivors with severe obesity decreased from 60% to 35%. These findings suggest that AOMs are effective for weight reduction in survivors of AYA cancer.
No takes yet. Share an insight, caveat, or question.
Berkman et al. (2025) conducted a cohort in Adolescent and young adult (AYA) cancer survivors. Anti-obesity medications (AOMs) vs. Pre-AOM baseline was evaluated on ≥5% weight reduction. Anti-obesity medications led to ≥5% weight reduction in 63.4% of adolescent and young adult cancer survivors, with severe obesity decreasing from 60% to 35%.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: